ACH-TELMISARTAN TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

TELMISARTAN

Pieejams no:

ACCORD HEALTHCARE INC

ATĶ kods:

C09CA07

SNN (starptautisko nepatentēto nosaukumu):

TELMISARTAN

Deva:

40MG

Zāļu forma:

TABLET

Kompozīcija:

TELMISARTAN 40MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

15G/50G

Receptes veids:

Prescription

Ārstniecības joma:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Produktu pārskats:

Active ingredient group (AIG) number: 0138223001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2021-03-05

Produkta apraksts

ACH-Telmisartan - Product Monograph
_ _
_ _
_ _
_ _
_ _
_ _
Page 1 of 35
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ACH-TELMISARTAN
Telmisartan Tablets
Tablet, 40 mg and 80 mg, Oral
Manufacturer’s Standard
Angiotensin II AT
1
Receptor Blocker
Accord Healthcare Inc.
3535 boul. St. Charles, Suite 704
Kirkland, QC, H9H 5B9
Canada
Date of Initial Authorization:
June 7, 2013
Date of Revision:
June 26, 2023
SUBMISSION CONTROL NUMBER: 271374
ACH-Telmisartan - Product Monograph
_ _
_ _
_ _
_ _
_ _
_ _
Page 2 of 35
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
06/2023
7 WARNINGS AND PRECAUTIONS
06/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION.......................................................................
4
1
INDICATIONS
..................................................................................................................
4
1.1
Pediatrics
...............................................................................................................
4
1.2
Geriatrics
...............................................................................................................
4
2
CONTRAINDICATIONS.....................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................................ 5
4
DOSAGE AND ADMINISTRATION
....................................................................................
5
4.1
Dosing Considerations
............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.................................................